Deborah A. Tweddle
YOU?
Author Swipe
View article: Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open
PDX data and clinical data
View article: Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open
GEMM ALK inhibitor data
View article: Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open
Supplementary methods, supplementary tables, supplementary figure legends
View article: Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open
Cell line growth curves and PDX data for idasanutlin combination
View article: Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open
PDTC experimental data
View article: Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open
Cell line and PDX genetics
View article: Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology Open
Background The Experimental Cancer Medicine Centre (ECMC) Network supports UK-wide access to experimental cancer therapies, many of which require specific genomic alterations. This study aimed to develop expert consensus on essential genes…
View article: Harmonization of Reporting for Detection of ALK Genetic Alterations in Neuroblastoma
Harmonization of Reporting for Detection of ALK Genetic Alterations in Neuroblastoma Open
In high-risk neuroblastoma, identification of ALK activating genetic alterations is considered for clinical decision-making in a relapse setting or more recently in frontline treatment. The accurate diagnosis of genetic alterations require…
View article: Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA
Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA Open
Neuroblastoma (NB) is an aggressive childhood cancer requiring intensive multimodal therapies in high-risk (HRNB) patients. Currently, invasive surgical biopsies are required to classify NB risk group and assign treatment based on the tumo…
View article: Supplementary Figure S6 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S6 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Cohort-wide oncoplot for tissue vs cfDNA variants.
View article: Supplementary Figure S9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
STRINGDB interaction networks of disease-specific fragmentomics clusters.
View article: Supplementary Table 7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Paediatric cancer specific targeted panel.
View article: Supplementary Table 9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Paediatric cancer specific cfDNA panel (ctPC Panel).
View article: Supplementary Figure S10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Similarity matrix for TFBS sets.
View article: Supplementary Figure S4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Top relapse-specific copy number events.
View article: Supplementary Table 2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Relapse vs. primary somatic variants.
View article: Supplementary Table 8 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 8 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
RMH solid tumour panel.
View article: Supplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Disease-specific diagnostic vs. relapse sequence variants.
View article: Supplementary Figure S12 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S12 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Fragmentomics reveals disease specific differential accessibility at transcription factor binding sites.
View article: Supplementary Table 11 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 11 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Samples used for lcWGS.
View article: Supplementary Figure S8 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S8 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Concordance between ctDNA and tissue copy number profiles.
View article: Supplementary Table 4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Relapse Vs. primary copy number variants.
View article: Supplementary Table 1 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 1 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Patient information.
View article: Data from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Data from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
We profiled a large heterogeneous cohort of matched diagnostic relapse tumor tissue and paired plasma-derived cell-free DNA (cfDNA) from patients with relapsed and progressive solid tumors of childhood. Tissue and cfDNA sequencing results …
View article: Supplementary Figure S11 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S11 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Fragmentomics reveals disease specific differential accessibility at transcription factor binding sites.
View article: Supplementary Figure S3 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Figure S3 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Primary vs. relapse copy number profiles.
View article: Supplementary Table 10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Samples used for PanelSeq.
View article: Supplementary Table 6 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 6 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Fragmentomics clusters.
View article: Supplementary Table 5 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 5 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Tissue Vs cfDNA variants.
View article: Supplementary Table 3 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Supplementary Table 3 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States Open
Fusions from RNA panel.